Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2011

01-08-2011 | Research Article

CTGF is overexpressed in papillary thyroid carcinoma and promotes the growth of papillary thyroid cancer cells

Authors: Lei Cui, Qing Zhang, Zhengfa Mao, Jixiang Chen, Xuqing Wang, Jianguo Qu, Jianxin Zhang, Dayong Jin

Published in: Tumor Biology | Issue 4/2011

Login to get access

Abstract

Connective tissue growth factor (CTGF or CCN2), which belongs to the CCN family, is a secreted protein. It has been implicated in various biological processes, such as cell proliferation, migration, angiogenesis, and tumorigenesis. In this study, we found that CTGF expression level was elevated in primary papillary thyroid carcinoma (PTC) samples and correlated with clinical features, such as metastasis, tumor size, and clinical stage. Overexpression of CTGF in PTC cells accelerated their growth in liquid culture and soft agar as well as protecting PTC cells from apoptosis induced by IFN-gamma treatment. Downregulation of CTGF in PTC cells inhibits cell growth in liquid culture and soft agar and induces the activation of caspase pathway and sensitized PTC cells to apoptosis. Our data suggest that CTGF plays an important role in PTC progression by supporting tumor cell survival and drug resistance, and CTGF may be used as a potential tumor marker for PTC diagnosis.
Literature
1.
Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985–1995 [see comments] (translated from English). Cancer. 1998;83(12):2638–48 (in English).PubMedCrossRef
2.
Liu S, Semenciw R, Ugnat AM, Mao Y. Increasing thyroid cancer incidence in Canada, 1970–1996: time trends and age-period-cohort effects. Br J Cancer. 2001;85(9):1335–9.PubMedCrossRef
3.
Farid NR. P53 mutations in thyroid carcinoma: tidings from an old foe. J Endocrinol Investig. 2001;24(7):536–45.
4.
Prante O et al. Regulation of uptake of 18F-FDG by a follicular human thyroid cancer cell line with mutation-activated K-ras. J Nucl Med. 2009;50(8):1364–70.PubMedCrossRef
5.
Christine J et al. BRAFV600E mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery. 2010;148(6):1139–46.CrossRef
6.
McIver B, Grebe SK, Eberhardt NL. The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma. Curr Drug Targets Immune Endocr Metabol Disord. 2004;4(3):221–34.PubMedCrossRef
7.
Anna G et al. Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application. Endocr J. 2011;58(1):31–8.CrossRef
8.
Asmis LM, Gerber H, Kaempf J, Studer H. Epidermal growth factor stimulates cell proliferation and inhibits iodide uptake of FRTL-5 cells in vitro. J Endocrinol. 1995;145(3):513–20.PubMedCrossRef
9.
Nishida T et al. CCN family 2/connective tissue growth factor (CCN2/CTGF) regulates the expression of Vegf through Hif-1alpha expression in a chondrocytic cell line, HCS-2/8, under hypoxic condition. Bone. 2009;44(1):24–31.PubMedCrossRef
10.
Bork P. The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett. 1993;327(2):125–30.PubMedCrossRef
11.
12.
Yang F et al. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res. 2005;65(19):8887–95.PubMedCrossRef
13.
Xie D et al. Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res. 2004;10(6):2072–81.PubMedCrossRef
14.
Wang MY et al. Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1. Cancer Res. 2009;69(8):3482–91.PubMedCrossRef
15.
Deng YZ et al. Connective tissue growth factor is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenicity through beta-catenin-T-cell factor/Lef signaling. J Biol Chem. 2007;282(50):36571–81.PubMedCrossRef
16.
Chen PP et al. Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS ONE. 2007;2(6):e534.PubMedCrossRef
17.
Lin BR et al. Connective tissue growth factor inhibits metastasis and acts as an independent prognostic marker in colorectal cancer. Gastroenterology. 2005;128(1):9–23.PubMedCrossRef
18.
Shakunaga T et al. Expression of connective tissue growth factor in cartilaginous tumors. Cancer. 2000;89(7):1466–73.PubMedCrossRef
19.
Yin D et al. CTGF associated with oncogenic activities and drug resistance in glioblastoma multiforme (GBM) (translated from English) Int J Cancer 2010 (in English)
20.
Selzer E, Wilfing A, Sexl V, Freissmuth M. Effects of type I-interferons on human thyroid epithelial cells derived from normal and tumour tissue (translated from English). Naunyn Schmiedebergs Arch Pharmacol. 1994;350(3):322–8 (in English).PubMedCrossRef
21.
22.
Liu LY, Han YC, Wu SH, Lv ZH. Expression of connective tissue growth factor in tumor tissues is an independent predictor of poor prognosis in patients with gastric cancer (translated from English). World J Gastroenterol. 2008;14(13):2110–4 (in English).PubMedCrossRef
23.
Chang CC et al. Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis (translated from English). J Natl Cancer Inst. 2004;96(5):364–75 (in English).PubMedCrossRef
24.
Chen PS et al. CTGF enhances the motility of breast cancer cells via an integrin-alphavbeta3-ERK1/2-dependent S100A4-upregulated pathway (translated from English). J Cell Sci. 2007;120(Pt 12):2053–65 (in English).PubMedCrossRef
25.
Alvarez H et al. Serial analysis of gene expression identifies connective tissue growth factor expression as a prognostic biomarker in gallbladder cancer (translated from English). Clin Cancer Res. 2008;14(9):2631–8 (in English).PubMedCrossRef
Metadata
Title
CTGF is overexpressed in papillary thyroid carcinoma and promotes the growth of papillary thyroid cancer cells
Authors
Lei Cui
Qing Zhang
Zhengfa Mao
Jixiang Chen
Xuqing Wang
Jianguo Qu
Jianxin Zhang
Dayong Jin
Publication date
01-08-2011
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2011
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-011-0173-6

Other articles of this Issue 4/2011

Tumor Biology 4/2011 Go to the issue

Research Article

EBV-encoded LMP1 increases nuclear β-catenin accumulation and its transcriptional activity in nasopharyngeal carcinoma

Research Article

Analysis of nuclear nestin localization in cell lines derived from neurogenic tumors

Research Article

Expression analysis and clinical evaluation of kallikrein-related peptidase 10 (KLK10) in colorectal cancer

Research Article

Klotho, an anti-senescence related gene, is frequently inactivated through promoter hypermethylation in colorectal cancer

Research Article

Zinc induces cell cycle arrest and apoptosis by upregulation of WIG-1 in esophageal squamous cancer cell line EC109

Research Article

Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits